Back to top
more

Iovance Biotherapeutics (IOVA)

(Delayed Data from NSDQ)

$11.87 USD

11.87
8,980,181

+0.25 (2.15%)

Updated Aug 23, 2024 04:00 PM ET

After-Market: $11.82 -0.05 (-0.42%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Iovance (IOVA) Q2 Earnings Miss, Lifileucel BLA on Track

by Zacks Equity Research

Iovance Biotherapeutics (IOVA) reports a wider-than-expected second-quarter loss. The company is on track to initiate a rolling BLA submission for lifileucel in melanoma later this month.

Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for XBI

Iovance (IOVA) Pipeline Aids Growth Amid Lack of Marketed Drugs

by Zacks Equity Research

Iovance (IOVA) is progressing well with the clinical development of its pipeline candidates. It expects to file a BLA with the FDA, seeking approval for its lead candidate to treat metastatic melanoma, this August.

Iovance (IOVA) Down After Announcing Data From Melanoma Study

by Zacks Equity Research

Results from a cohort of the phase II study evaluating Iovance's (IOVA) melanoma candidate were not as superior as data from another cohort of the same study.

Iovance (IOVA) Q1 Earnings Beat, Lifileucel BLA on Track

by Zacks Equity Research

Iovance Biotherapeutics (IOVA) reports a narrower-than-expected first-quarter loss. The company is on track to file a regulatory submission for lifileucel in melanoma in August 2022.

    Iovance (IOVA) Stock Rallies 33% in a Month: Here's Why

    by Zacks Equity Research

    Iovance (IOVA) to complete the FDA filing for its lead candidate in melanoma by August. It will start a clinical study for its first TALEN-edited TIL therapy for two advanced cancer indications later this year.

    Iovance (IOVA) to Seek FDA Nod for Melanoma Therapy in August

    by Zacks Equity Research

    Iovance (IOVA) expects to complete FDA filing for lifileucel in metastatic melanoma by August 2022. It also intends to start a phase III combo study with lifileucel in melanoma in late 2022.

      Iovance (IOVA) to Start Clinical Studies for TIL Therapy

      by Zacks Equity Research

      Iovance (IOVA) gets FDA nod to start clinical study for IOV-4001, which utilizes the technology licensed from Cellectis. A clinical study in melanoma or NSCLC indication is expected to begin in 2022.

      Iovance (IOVA) Announces Wider-Than-Anticipated Q4 Loss

      by Zacks Equity Research

      Iovance Biotherapeutics' (IOVA) fourth-quarter loss is wider than expected. The company is on track to file regulatory submission for lifileucel in melanoma by first-half 2022.

      Iovance (IOVA) Reports Wider-Than-Anticipated Loss in Q3

      by Zacks Equity Research

      Iovance Biotherapeutics' (IOVA) third-quarter loss is wider than expected. The company is progressing well in terms of development of pipeline candidates.

      Iovance Biotherapeutics (IOVA) Sees Hammer Chart Pattern: Time to Buy?

      by Zacks Equity Research

      Iovance Biotherapeutics (IOVA) has been struggling lately, but the selling pressure may be coming to an end soon.

      Wall Street Analysts Think Iovance Biotherapeutics (IOVA) Could Surge 52%: Read This Before Placing a Bet

      by Zacks Equity Research

      The average of price targets set by Wall Street analysts indicates a potential upside of 51.8% in Iovance Biotherapeutics (IOVA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

      Does Iovance Biotherapeutics (IOVA) Have the Potential to Rally 49% as Wall Street Analysts Expect?

      by Zacks Equity Research

      The consensus price target hints at a 49% upside potential for Iovance Biotherapeutics (IOVA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

      HOOKIPA (HOOK), Merck Collaborate to Treat Head & Neck Cancers

      by Zacks Equity Research

      HOOKIPA (HOOK) collaborates with Merck (MRK) to evaluate the combination of its immunotherapy program, HB-200, with Merck's Keytruda for advanced head and neck squamous cell carcinoma.

      Implied Volatility Surging for Iovance (IOVA) Stock Options

      by Zacks Equity Research

      Investors need to pay close attention to Iovance (IOVA) stock based on the movements in the options market lately.

      Iovance (IOVA) Q2 Earnings Miss Estimates, Pipeline in Focus

      by Zacks Equity Research

      Iovance's (IOVA) second-quarter loss is wider than expected. The company is progressing well in terms of development of its pipeline candidates.

      Iovance (IOVA) Announces Lung Cancer Study Data on TIL Therapy

      by Zacks Equity Research

      Iovance (IOVA) is developing several TIL therapies, including LN-145, in a mid-stage study. Data from the lung cancer cohort evaluating LN-145 monotherapy demonstrates an ORR of 21.4%.

      Iovance (IOVA) Falls on Negative Lifileucel Regulatory Update

      by Zacks Equity Research

      Iovance (IOVA) announces delay in BLA submission for its lead pipeline candidate, lifileucel for metastatic melanoma due to potency assay issue.

      Is the Options Market Predicting a Spike in Iovance Biotherapeutics (IOVA) Stock?

      by Zacks Equity Research

      Investors need to pay close attention to Iovance Biotherapeutics (IOVA) stock based on the movements in the options market lately.

        Iovance (IOVA) Q1 Earnings Miss Estimates, Pipeline in Focus

        by Zacks Equity Research

        Iovance's (IOVA) first-quarter earnings lag estimates. The company is progressing well in terms of development of its lead pipeline candidate.

        Why Is Iovance Biotherapeutics (IOVA) Down 21.5% Since Last Earnings Report?

        by Zacks Equity Research

        Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

        Iovance (IOVA) Q4 Earnings Miss Estimates, Pipeline in Focus

        by Zacks Equity Research

        Iovance's (IOVA) fourth-quarter earnings miss estimates. The company is progressing well with development of its lead pipeline candidate.

        Why Is Iovance Biotherapeutics (IOVA) Up 6.7% Since Last Earnings Report?

        by Zacks Equity Research

        Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

        Iovance (IOVA) Q3 Earnings Beat Estimates, Pipeline in Focus

        by Zacks Equity Research

        Iovance's (IOVA) third-quarter earnings beat estimates. The company is progressing well with development of its lead pipeline candidate.

        Iovance Stock Down on Delay in Filing for Melanoma Candidate

        by Zacks Equity Research

        Iovance (IOVA) delays its application to the FDA for a tumor-infiltrating lymphocyte (TIL) therapy, lifileucel, for the treatment of metastaic melanoma until later in 2021.